Aspirin Improves Bone Density in Mouse Osteoporosis

Stimulates bone production and inhibits bone resorption

MONDAY, July 14 (HealthDay News) -- Aspirin treatment of estrogen-deficient osteoporosis in mice can improve bone mineral density by stimulating the production of bone-forming cells and inhibiting bone-resorbing cells, researchers report in the July issue of PLoS ONE.

Takayoshi Yamaza, Ph.D. from the University of Southern California School of Dentistry in Los Angeles, and colleagues examined the role of bone marrow mesenchymal stem cells in mice with ovariectomy-induced osteoporosis, and the effect of aspirin treatment on the balance between bone resorption and bone formation in these mice.

The researchers found that activated T cells mediated impairment of bone marrow mesenchymal stem cells primarily due to the induction of cell death, which could be inhibited by aspirin treatment. Aspirin also increased osteogenesis and inhibited osteoclast activity, improving bone mineral density, they report.

"Our findings have revealed a novel osteoporosis mechanism in which activated T cells induce bone marrow mesenchymal stem cell apoptosis via Fas/Fas ligand pathway and suggested that pharmacologic stem cell-based intervention by aspirin may be a new alternative in osteoporosis treatment including activated osteoblasts and inhibited osteoclasts," Yamaza and colleagues conclude.

Full Text

Physician's Briefing